Primus Anabolics

QuickStart Highlights

Tirzepatide is a novel 39-amino acid dual incretin receptor agonist that activates both GLP-1 and GIP receptors, improving glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Its ~5-day half-life allows for convenient subcutaneous dosage once per week.

Clinical trials demonstrate superior glycemic control and weight reduction compared to selective GLP-1 agonists.

Reconstitution: Add 3.0 ml of bacteriostatic water → 10.0 mg/ml concentration.
Typical weekly interval: 2.5-15 mg once a week (gradual 4-week titration steps).
Easy measurement: At 10.0 mg/ml, 1 unit = 0.01 ml = 100 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4°F); after reconstitution, refrigerate at 2–8°C (35.6–46.4°F); use within 28 days.

Dosage and Reconstitution Guide

Subcutaneous, once a week
Standard / gradual approach (3 ml = 10.0 mg/ml)

Phase	Weekly dose (mg)	Units (per injection)	Volumen (mL)
Weeks 1–4	2.5 mg	25 units x 1 injection	0.25 mL
Weeks 5–8	5 mg	50 units x 1 injection	0.50 mL
Weeks 9–12	7.5 mg	75 units x 1 injection	0.75 ml
Weeks 13-16	10 mg	100 units x 1 injection	1.0 mL

Frequency: Inject once per week subcutaneously on the same day each week.

All doses fit in a single 1 ml insulin syringe at this concentration. Dose increases occur every 4 weeks to minimize gastrointestinal side effects.

Higher doses (12.5-15 mg/week) may be used in later phases if tolerated and clinically indicated.

Reconstitution Steps

Draw 3.0 ml of bacteriostatic water with a sterile syringe.
Inject slowly down the side of the vial; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label with reconstitution date and refrigerate, protected from light.
Use within 28 days of reconstitution.

Required Supplies

Plan based on an 8-16 week protocol with gradual titration (once-a-week dosing).

Peptide vials (Tirzepatide, 30 mg each):
- 8 weeks (2.5→5 mg/week): ~30 mg total ≈ 1 vial
- 12 weeks (2.5→7.5 mg/week): ~60 mg total ≈ 2 vials
- 16 weeks (2.5→10 mg/week): ~100 mg total ≈ 4 vials
Bacteriostatic water (10 ml bottles): Use 3.0 ml per vial for reconstitution.
- 8 weeks (1 vial): 3 ml → 1 × 10 mL bottle
- 12 weeks (2 viales): 6 ml → 1 × 10 mL bottle
- 16 weeks (4 viales): 12 ml → 2 × 10 ml bottles

Protocol Overview

Concise summary of the once-per-week regimen.

Objective: Support glycemic control, weight management, and metabolic health through dual incretin receptor activation.
Schedule: Weekly subcutaneous injection on the same day of each week for 12-16 weeks.
Dose range: 2.5-15 mg weekly with 4-week titration intervals.
Reconstitution: 3.0 ml per 30 mg vial (10.0 mg/ml) — all doses fit in a single syringe.
Storage: Lyophilized frozen; reconstituted refrigerated for a maximum of 28 days.

Dosing Protocol

Suggested weekly titration approach.

Start: 2.5 mg once a week for 4 weeks (initiation dose)
Escalation: Increase by 2.5 mg every 4 weeks as tolerated.
Maintenance: 5-15 mg weekly depending on response and tolerability.
Frequency: Once per week (subcutaneous), the same day each week.
Timing: Any time of day; with or without food; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality.

Lyophilized: Store at −20 °C (−4 °F) in dry and dark conditions; minimize exposure to moisture.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reformulated solution.
Shelf life: Use reconstituted solution within 28 days.
Allow vials to reach room temperature before opening to reduce condensation absorption.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes; dispose of in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
All doses through 10 mg/week fit in a single 1 ml syringe at this concentration.
Inject slowly; wait a few seconds before removing the needle.
Document weekly dose, date, and injection site to maintain consistency.
Gastrointestinal effects (nausea, diarrhea) are common initially; gradual titration helps minimize them.

How it works

Tirzepatide is a novel dual agonist that simultaneously activates GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors.

This dual mechanism improves glucose-dependent insulin secretion while suppressing glucagon release, slowing gastric emptying, and promoting satiety through central appetite regulation. The added GIP activity appears to synergistically amplify metabolic effects beyond GLP-1 alone, contributing to superior weight reduction observed in clinical trials.

Its ~5-day half-life allows for convenient once-per-week administration.

Potential Benefits and Side Effects

Observations from clinical trials and published literature.

Glycemic control: Significant HbA1c reductions in type 2 diabetes trials
Weight reduction: Clinical trials report substantial body weight loss (up to ~11 kg more than GLP-1 RA comparators over 26 weeks at higher doses)
Cardiovascular markers: Improvements in lipid profiles and blood pressure observed in some studies
Common adverse effects: gastrointestinal (nausea, diarrhea, vomiting, constipation), typically mild to moderate and dose-dependent; gradual titration reduces incidence
Injection site reactions: occasional mild redness or irritation at subcutaneous injection sites.

Lifestyle Factors

Complementary strategies for the best results.

Combine with a balanced and calorie-appropriate diet; reduced appetite may naturally decrease intake.
Prioritize protein to preserve lean mass during weight loss.
Combine resistance training and aerobic activity to support metabolic health.
Stay hydrated, especially considering potential gastrointestinal effects.
Prioritize sleep and stress management to support adherence and recovery.

Injection Technique

General subcutaneous guidance from best-practice clinical resources

Clean vial stopper and skin with alcohol; let dry.
Pinch a skin fold; insert the needle at 45–90° into the subcutaneous tissue.
Do not aspirate for subcutaneous injections; inject slowly and steadily.
Rotate sites systematically (abdomen avoiding the 2-inch radius around the navel, outer thighs, upper arms) to avoid lipohypertrophy.